Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
Fiche publication
Date publication
janvier 2021
Journal
JACC. Heart failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca HP, Clark AL, Cosmi F, Cuthbert J, Díez J, Edelmann F, Girerd N, González A, Grojean S, Hazebroek M, Khan J, Latini R, Mamas MA, Mariottoni B, Mujaj B, Pellicori P, Petutschnigg J, Pieske B, Rossignol P, Rouet P, Staessen JA, Cleland JGF, Heymans S, Zannad F,
Lien Pubmed
Résumé
This study sought to further understand the mechanisms underlying effect of spironolactone and assessed its impact on multiple plasma protein biomarkers and their respective underlying biologic pathways.
Mots clés
fibrosis, heart failure prevention, inflammation, renin-angiotensin-aldosterone system, spironolactone
Référence
JACC Heart Fail. 2021 Jan 28;: